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Abstract
Background: In this study, we tested five series of pyrazole-5-carboxamide compounds (n = 55) for activity against
parasitic stages of the nematode Haemonchus contortus (barber’s pole worm), one of the most pathogenic parasites
of ruminants.
Methods: In an optimised, whole-organism screening assay, using exsheathed third-stage (xL3) and fourth-stage
(L4) larvae, we measured the inhibition of larval motility and development of H. contortus.
Results: Amongst the 55 compounds, we identified two compounds (designated a-15 and a-17) that reproducibly
inhibit xL3 motility as well as L4 motility and development, with IC50 values ranging between ~3.4 and 55.6 μM. We
studied the effect of these two ‘hit’ compounds on mitochondrial function by measuring oxygen consumption. This
assessment showed that xL3s exposed to each of these compounds consumed significantly less oxygen and had
less mitochondrial activity than untreated xL3s, which was consistent with specific inhibition of complex I of the
respiratory electron transport chain in arthropods.
Conclusions: The present findings provide a sound basis for future work, aimed at identifying the targets of compounds
a-15 and a-17 and establishing the modes of action of these chemicals in H. contortus.
Keywords: Haemonchus contortus, Phenotypic screening, Tolfenpyrad, Synthetic pyrazole-5-carboxamide derivatives,
Mitochondrial respiratory chain
Background
Synthetic pyrazole-5-carboxamide derivatives, such as
tebufenpyrad and tolfenpyrad, are important pesticides
which are recognized to inhibit complex I of the mito-
chondrial electron transport (respiratory) chain [1, 2].
Tebufenpyrad, which was first discovered in 1987 by
Mitsubishi Kasei Co., Ltd., has known activity against
selected Homoptera and phytophagous mites [3].
Tolfenpyrad was discovered by Mitsubishi Chemical
Corporation (now Nihon Nohyaku Co., Ltd.) and developed
for the control of various agricultural pests, including
Acarina, Coleoptera, Diptera, Hemiptera, Lepidoptera and
Thysanoptera (Arthropoda); the latter chemical is active
mainly upon contact with egg, larval, nymphal and/or adult
stages [4]. Because of the effectiveness of these two
pyrazole-5-carboxamides in controlling such agricultural
pests [4, 5], there has been a considerable commercial inter-
est in synthesizing various structural derivatives, with
changes being made to the pyrazole and/or benzene rings
[5–12], but little work has been done to alter the chemical
bridge between the pyrazole and benzene rings (cf. [2]).
Although tebufenpyrad, tolfenpyrad and selected de-
rivatives [2] have been developed to kill arthropod pests,
we recently showed, in a compound screen of the ‘Patho-
gen Box’ (www.pathogenbox.org) from the Medicines for
Malaria Ventures (MMV; www.mmv.org), that the latter
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compound has an exquisite in vitro activity against parasitic
stages of the barber’s pole worm, Haemonchus contortus
(Nematoda: Strongylida) [13]. Indeed, tolfenpyrad reprodu-
cibly and irreversibly inhibits the motility of exsheathed
third-stage (xL3s) and fourth-stage larvae (L4s) of this para-
sitic nematode, and also the growth and development of
L4s, with IC50 values ranging between 0.03 and 3.1 μM
after 72 h of exposure. We demonstrated that xL3s exposed
to tolfenpyrad consumed significantly less oxygen than un-
exposed xL3s, which was consistent with a specific inhib-
ition of complex I of the respiratory electron transport
chain in the mitochondrion (cf. [1]). In vitro cytotoxicity
data indicated that tolfenpyrad is ≥ 18-fold more selective
for H. contortus than a mammalian cell line [13], raising the
possibility of repurposing this agent against (at least some)
parasitic nematodes and/or hit-to-lead optimisation.
In general terms, this evidence suggested that some
pyrazole-5-carboxamide compounds developed as agri-
cultural pesticides (against arthropods of plants) might
also be able to be repurposed to other ecdysozoans, such
as nematodes, provided that they are sufficiently safe for
application/administration to animals and/or the envir-
onment. Therefore, we sourced two published series of
pyrazole-5-carboxamides [2, 14] and three new series of
new pyrazole-5-carboxamides analogues (Song et al., un-
published). The availability of this small library provided
us with an opportunity to logically extend our recent
study [13]. Here, we evaluated the activity of these
pyrazole-5-carboxamides derivatives (n = 55) against
parasitic stages of the nematode Haemonchus contortus
and compared their potency with the two original, com-
mercially available chemicals, tebufenpyrad and tolfen-
pyrad. We used this whole-organism screening assay to
measure the inhibition of larval motility and develop-
ment of H. contortus, and then investigated the effect of
any active compound on mitochondrial function by
measuring oxygen consumption in this nematode.
Methods
Procurement of H. contortus
The Haecon-5 strain of H. contortus was maintained in
experimental sheep as described previously [15] and in
accordance with institutional animal ethics guidelines
(permit no. 1413429; The University of Melbourne,
Australia). L3s were produced from H. contortus eggs by
incubating humidified faeces from infected sheep at 27 °C
for 1 week [15], sieved through nylon mesh (pore size:
20 μm) to remove debris or dead larvae and then stored at
10 °C for a maximum of 3 months. For screening and
basal oxygen consumption measurements (see following
Sub-sections), L3s were exsheathed and sterilised in
0.15% v/v sodium hypochlorite (NaClO) at 37 °C for
20 min [15]. Thereafter, xL3s were washed five times
in sterile physiological saline by centrifugation at
600× g (5 min) at 22–24 °C. Then, xL3s were imme-
diately suspended in Luria Bertani medium [LB: 10 g
of tryptone (cat no. LP0042; Oxoid, Hampshire,
England), 5 g of yeast extract (cat no. LP0042; Oxoid)
and 5 g of NaCl (cat. no. K43208004210; Merck,
Kenilworth, NJ, USA)] in 1 l of reverse-osmosis deio-
nised water). LB was autoclaved and supplemented
with 100 IU/ml of penicillin, 100 μg/ml of strepto-
mycin and 2.5 μg/ml of amphotericin (Fungizone, anti-
biotic - antimycotic; cat. no. 15240-062; Carlsbad, CA,
USA); this supplemented LB was designated LB*.
Pyrazole-5-carboxamide compounds
A total of 55 analogs of tebufenpyrad and tolfenpyrad
were derivatised (Additional file 1: Table S1). In brief,
pyrazole derivatives containing α-hydroxymethyl-N-ben-
zyl carboxamide, α-chloromethyl-N-benzyl carboxamide
and 4,5-dihydrooxazole moieties (a-1 to a-23) [2], carbo-
hydrazide (b-1 to b-7), imine, oxime ether, oxime ester,
and dihydroisoxazoline (c-1 to c-15) [14], oxazole (d-1
to d-8) and e-1 to e-2 (this study) were designed and
synthesized (Additional file 1: Table S1). In addition, tol-
fenpyrad (IUPAC name: 4-chloro-N-[[4-(1,1-dimethy-
lethyl)phenyl]methyl]-3-ethyl-1-methyl-1H-pyrazole-5-car
boxamide, cat. no. T535325, Toronto Research Chemicals,
Toronto, Ontario, Canada) and tebufenpyrad (IUPAC
name: 4-chloro-3-ethyl-1-methyl-N-[4-(p-tolyloxy)benzyl]
pyrazole-5-carboxamide, cat. no. T013500, Toronto Re-
search Chemicals, Canada) (99.9% purity) were purchased
from commercial suppliers; the former chemical was used
as a positive-reference compound (cf. [13]).
Screening of chemicals, inhibitory concentrations and
cytotoxicity assessment
All compounds (Additional file 1: Table S1) were pre-
pared as described previously [13] and screened (in trip-
licate) at a concentration of 100 μM on xL3s of H.
contortus in 96-well microculture plates using two
assay-control compounds, monepantel (Zolvix, Novartis
Animal Health, Basel, Switzerland) and moxidectin
(Cydectin, Virbac, France). In brief, compounds were
dissolved to a stock concentration of 10 mM in dimethyl
sulfoxide (DMSO, Ajax Finechem, Melbourne, Australia),
individually diluted to the final concentration of 100 μM
using LB*, and dispensed (in triplicate) into wells of the
96-well microculture plates (cat no. 3635; Corning Life
Sciences, Corning, NY, USA) using a multichannel pipette.
In addition, negative-controls (LB* and LB* + 0.5% DMSO;
six wells each) and positive-controls (final concentration
of 100 μM of monepantel and 100 μM of moxidectin; trip-
licate wells each) were included. Then, xL3s (~300/well)
were dispensed into wells of the plate. Following an incu-
bation for 72 h at 38 °C and 10% CO2, a video recording
(5 s) was taken of each well of the 96-well microculture
Jiao et al. Parasites & Vectors  (2017) 10:272 Page 2 of 7
plate (containing xL3s) using a grey-scale camera (Rolera
bolt, Q imaging Scientific Coms, Canada), and a motorised
X-Y axis stage (BioPoint 2, Ludl Electronics Products,
Hawthorne, NY, USA). Individual video recordings were
processed to calculate a motility index (MI) using an algo-
rithm described previously [13, 15]. MIs were normalised
to the positive- and negative-controls (to remove plate-to-
plate variation) using the program Prism (v.6 GraphPad
Software, USA). A compound was recorded as having activ-
ity if it reduced xL3 motility by ≥ 70% after 72 h of
incubation.
Anti-xL3 activity of individual compounds was con-
firmed, and half maximum inhibitory concentration
(IC50) values estimated from dose-response curves (24 h,
48 h and 72 h). Compounds that reduced the motility of
xL3s were also tested for their ability to inhibit the de-
velopment of xL3s to L4s, and the motility of L4s. All
assays (for xL3 motility, and L4 development and motil-
ity) were performed in triplicate, between 3-5 times on
different days. To determine IC50 values, the data from
each assay (xL3 motility, L4 motility and development)
were converted to a percentage with reference to the
negative-control (LB* + 0.5% DMSO), and IC50 values
determined using a variable slope four-parameter equa-
tion, constraining the top value to 100% and using a
least squares (ordinary) fit model (v.6 GraphPad Soft-
ware). The toxicity of selected compounds was measured
by assessing their inhibition of the proliferation of hu-
man neonatal foreskin fibroblast (NFF) cells as described
previously [16]. Selectivity indices (SIs) were calculated
as follows: IC50 for NFF cells / IC50 for H. contortus).
Oxygen consumption assay
Oxygen consumption (reflecting oxidative phosphoryl-
ation) was measured in the medium containing H.
contortus xL3s (n = 600 per well) in the presence (50 μM
or 100 μM) or absence of individual chemical com-
pounds using the Seahorse XFe96 analyzer (Seahorse
Biosciences, Agilent Technologies, Santa Clara, CA,
USA) as described previously with minor modification
[13]. In brief, xL3s were dispensed into XFe96 cell cul-
ture microplates (Seahorse Biosciences, Aligent Tech-
nologies) at a density of 600 xL3s per well in 150 μl of
XF Base medium (Seahorse Bioscience, USA), supple-
mented with 4.5 g/l of glucose, 0.5 mM of sodium pyru-
vate and 2 mM of glutamine (Sigma-Adlrich, St. Louis,
MI, USA) (pH = 7.4). Four wells contained XF Base
medium alone and served as normalisation controls.
Subsequently, compounds dissolved in 25 μl of XF Base
medium were individually loaded into the injection ports
(in quadruplicate), and programmed to dispense into the
XFe96 microplate after 5 measurements of respiration at
6 min intervals (2 min-mix; 4 min-measure). Using this
approach, xL3s were exposed to compound concentrations
of 100 μM, 50 μM and 0 μM. Respiration rates were mea-
sured every 6 min for a period of 180 min. Assays were re-
peated three times on separate days.
Results
In the primary screen of the 55 test compounds (Fig. 1),
two pyrazole-5-carboxamide derivatives, a-15 and a-17,
were recorded to inhibit xL3 motility by ≥ 70% at con-
centrations of 50 μM or 100 μM, both revealing a
straight phenotype (Fig. 1; Additional file 2). Subsequent
assays using xL3s of H. contortus showed that the po-
tency of these two test compounds at 72 h of incubation
(IC50 values = 55.63 ± 0.18 μM and 51.60 ± 1.41 μM, re-
spectively) was considerably less than tolfenpyrad (IC50
value = 3.05 ± 0.47 μM) (Fig. 2; Table 1).
In the L4 motility assay, test compounds a-15, a-17
and tolfenpyrad all had significant inhibitory activities,
but IC50 values of the test compounds (~15–26 μM) at
Fig. 1 Primary screening of compounds on Haemonchus contortus. Synthetic pyrazole-5-carboxamides (n = 55) were tested for inhibition of motility of
exsheathed third-stage larvae (xL3) of H. contortus at a concentration of 100 μM (after 72 h of exposure). Tolfenpyrad, monepantel and/or moxidectin
were also included as control compounds; tolfenpyrad was used as the positive reference-control, as it has known activity against xL3s and L4s of H.
contortus [13]. Two active compounds, a-15 and a-17, inhibited xL3 motility by≥ 70%. Supplementary file 2 shows the “straight” phenotype in larvae
exposed to a-15 and a-17, similar to that of the tolfenpyrad control
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24 h, 48 h and 72 h were considerably greater than those
of the reference control (tolfenpyrad; 0.03 ± 0.02 μM) at
the 72 h time point (Table 1). In the L4 development
assay (at 7 days), a-15 (IC50 of 3.97 ± 0.35 μM) and a-17
(IC50 of 3.42 ± 0.50 μM) had significantly less inhibitory
effect on the L4 development than did tolfenpyrad
(IC50of 0.08 ± 0.01 μM; one-way ANOVA (F(2,6) =
35.52, P = 0.0005) and Dunnett’s multiple comparison
test (P = 0.0004 for a-15, and P = 0.001 for a-17)).
Interestingly, while tolfenpyrad had the expected
Fig. 2 Dose-response curves. The effects of the active pyrazole-5-carboxamide test compounds, a-15 and a-17, tolfenpyrad and tebufenpyrad on
parasitic stages of Haemonchus contortus in vitro. Inhibition of the motility of third-stage larvae (xL3s) at 24 h, 48 h and 72 h (a) for individual compounds
motility (b) and inhibition of development (c) of fourth-stage larvae (L4s) after seven days. Each data point represents the mean of three experiments
(± standard error of the mean, SEM)
Table 1 In vitro activity of test compounds. Comparison of activity of compounds a-15 and a-17 with tolfenpyrad and tebufenpyrad on
the motility of exsheathed third-stage (xL3) and fourth-stage (L4) larvae of Haemonchus contortus (after 24 h, 48 h and 72 h of exposure)
and on the development of L4 (after 7 days of exposure)
Compound Half maximum inhibitory concentration (IC50 μM)
xL3 motility L4 motility L4 development
24 h 48 h 72 h 24 h 48 h 72 h 7 days
a-15 – – 55.63 ± 0.18 – – 26.31a 3.97 ± 0.35
a-17 – – 51.60 ± 1.41 – – 15.58a 3.42 ± 0.50
Tolfenpyrad 2.98 ± 0.50 3.85 ± 1.33 3.05 ± 0.47 0.12 ± 0.07 0.06 ± 0.02 0.03 ± 0.02 0.08 ± 0.01
Tebufenpyrad na na na > 100 > 100 > 100 6.70a
aHalf maximum inhibitory concentration could not be accurately calculated by the log (agonist) versus response - variable slope (four parameter) equation, a IC50
value was estimated
na no activity; “–” indicates where IC50 values were not determined if the log(agonist) vs response - variable slope (four parameters) model could not be used to
fit the curve
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inhibitory effect on the motility of xL3 and L4 stages
(cf. [13]), tebufenpyrad reduced the motility and de-
velopment of L4s, but not of xL3s. Using available
cytotoxicity information (cf. Table 2), selective indices
(SIs) of a-15 (1.2, 2.5 and 16.8), a-17 (i.e. 1.4, 4.6 and
21.1) and tolfenpyrad (i.e. > 16, 1667 and 625) for
xL3 motility, L4 motility and L4 development, re-
spectively, were relatively high for the L4s. Subse-
quently, it was assessed whether a-15 and a-17 would
inhibit mitochondrial respiration in xL3s of H. contor-
tus by measuring oxygen consumption over time
(Fig. 3). The results showed that a-15, a-17- and
tolfenpyrad-treated xL3s consumed significantly less
oxygen than untreated xL3s at 50 μM and 100 μM
(one-way ANOVA (F(5,12) = 30.18, P < 0.0001 at
50 μM; F(5,12) = 34.57, P < 0.0001 at 100 μM) and
Dunnett’s multiple comparison test (P = 0.0001, 0.0001
and 0.0012 for a-15, a-17 and tolfenpyrad at 50 μM,
respectively; P = 0.0001, 0.0001 and 0.0016 for a-15,
a-17 and tolfenpyrad at 100 μM, respectively) (see
Fig. 3). As expected, based on its distinct mode of ac-
tion (cf. [17]), monepantel resulted in an inhibition of
larval motility and development, but it did not signifi-
cantly reduce oxygen consumption at the time-point
measured. Similarly, tebufenpyrad did not inhibit
respiration.
Discussion
The screening of 55 novel pyrazole-5-carboxamide de-
rivatives identified two compounds (designated a-15 and
a-17) with major activity against parasitic larval stages
(xL3 and L4) of H. contortus in vitro; IC50 values were
compared with tolfenpyrad, a pyrazole-5-carboxamide
insecticide, which was recently shown, for the first time,
to have substantial anthelmintic activity [13].
In the present study, compounds a-15 and a-17, like
tolfenpyrad, were shown to be more potent against L4s
than xL3s based on IC50 values (larval motility and de-
velopment). It is not known whether the potency
difference of each of these two compounds between
xL3s and L4s is due to variation in drug uptake, metab-
olism and/or mode of action, but it is likely that uptake
of the chemicals is considerably greater in the L4 stage,
as it has a functional pharynx and has a substantial nu-
trient requirement at this stage of development [18]. It
may also be that the target(s) of these chemicals is/are
expressed at a higher level in L4s than xL3s, achieving
greater binding and inhibitory effects in the nematode.
Although compounds a-15 and a-17 have less anthel-
mintic effect than tolfenpyrad on H. contortus (Table 1),
these compounds, which contain α-hydroxymethyl-N-
benzyl carboxamide, still have considerable anthelmintic
activity and appear to have a reasonable level of selectiv-
ity. A comparison with results from a previous study [2]
shows that both of the test compounds with anti-H. con-
tortus effect(s) also have considerable activity against
some plant-parasitic insects. This finding is in accord
with that of tolfenpyrad, which is reported to have a
relatively broad spectrum of activity against some ar-
thropods of plants [19] and selected nematode species
(ref. [13] and Preston et al., unpublished data).
Published information has implied that the mode of
action of some pyrazole derivatives, such as tolfen-
pyrad (fungicide or insecticide/acaricide), also relates
to a specific inhibition of complex I in the respiratory
electron transport chain in mitochondria (e.g. [14, 20].
Therefore, to provide support for the hypothesis that
compounds a-15 and a-17 act to disrupt or interrupt
mitochondrial function, resulting in a loss of parasite
motility and viability, oxygen consumption (via oxida-
tive phosphorylation) was measured in real-time in
xL3s of H. contortus using oxygen-sensitive probes
(cf. [21, 22]). Both compounds were shown (within
180 min) to reduce, in a dose-dependent manner,
oxygen consumption in H. contortus. This reduction
in consumption preceded the inhibition of motility
and development in this nematode, indicating that
each of the two compounds significantly decreases
oxidative phosphorylation, resulting (directly and/or
indirectly) in a substantial inhibition of larval motility
and development. The fact that these two compounds
induce a similar phenotype to that caused by tolfen-
pyrad [13] calls for future studies to confirm that the
electron transport chain is indeed the target. Such fu-
ture studies might be conducted in the free-living
nematode C. elegans (which is related to H. contor-
tus), because it is very amenable to gene knockdown
or knockout experiments, in contrast to H. contortus
[23–25]. In addition, other investigations could be
conducted in C. elegans to establish whether any
other pathways or (e.g. stress) responses are involved
in enabling or exacerbating the anthelmintic effects of
these compounds.
Table 2 Toxicity assessment. Compounds a-15 and a-17 were
tested for toxic effects on a human neonatal foreskin fibroblast
(NFF) cell line; tolfenpyrad was included as a reference control.
Selectivity indices of these compounds on the motility of
exsheathed third- and fourth-stage larvae (at 72 h) (xL3s and L4s)
and the development of L4s (at 7 days) were calculated using a
recognised formula [16]
Compound IC50 (μM) for
NFF cells
Selectivity index (SI) for H. contortus
xL3 motility L4 motility L4 development
a-15 66.72 ± 10.04 1.20 2.54 16.81
a-17 72.15 ± 1.61 1.40 4.63 21.10
Tolfenpyrad > 50 > 16.40 > 1666.70 > 625
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Interestingly, a previous study [26] had identified
nafuredin as a nematocide against H. contortus in vivo
in sheep; this chemical selectively targets mitochon-
drial complex I and disrupts the anaerobic NADH-
fumarate reductase respiratory pathway in helminths
[26]. Moreover, nafuredin has been shown to inhibit
mitochondrial complex I of Ascaris [27], and is more
than 1000-fold selective on this nematode than rat
liver cells [26, 28]. However, the original drug was
not of practical use or commercialised as a
nematocide, because it had been shown chemically
unstable in air due to the presence of oxygen-labile
conjugated dienes (cf. [28]). Adapting to the develop-
mental and environmental alterations, parasitic worms
use mitochondria complex I in respiratory chain, with
rhodoquinone and ubiquinone as electron receptors
in parasitic stages (anaerobic) and free-living larvae
stages (aerobic), respectively. Notably, mammalian complex
I of nematodes differs considerably from complex I in
mammals mitochondria [28–31]. Thus, based on evi-
dence from the present and previous studies, it ap-
pears that elements of mitochondrial respiratory chain
in parasitic worms seem to have promising potential
as targets for nematocides.
Conclusions
The present findings provide a sound basis for future
work, aimed at identifying the targets of compounds a-
15, a-17 and tolfenpyrad, and establishing the modes of
action of these chemicals in H. contortus. In addition,
medicinal chemistry-based structure activity relationship
(SAR) studies of pyrazole-5-carboxamides will enhance
understanding of which features of the pyrazole-5-
carboxamides skeleton are vital for anthelmintic activity.
Additional files
Additional file 1: Table S1. The 55 pyrazole-5-carboxamide derivatives
synthesized de novo. (DOCX 900 kb)
Additional file 2: Five-second video recordings of Haemonchus contortus
exsheathed third-stage larvae (xL3s) showing the “straight” phenotype induced
by exposure to the pyrazole-5-carboxamides a-15, a-17 (test compounds) or
tolfenpyrad (100 μM). Videos of xL3s exposed to the same concentration of
tebufenpyrad, monepantel or moxidectin, or not exposed to any compound
(LB* + 0.5% DMSO) were also included for comparison. (ZIP 148083 kb)
Abbreviations
IC50: Half maximum inhibitory concentration values; L4: fourth-stage larvae;
LB: Luria Bertani medium; MI: Motility index; MMV: Medicines for Malaria
Ventures; NFF cells: Human neonatal foreskin fibroblast cells; SAR: Structure
activity relationship; Sis: Selectivity indices; xL3: exsheathed third-stage larvae
Fig. 3 Respiration rates of Haemonchus contortus treated with test or control compounds in vitro. Panels a and b show individual curves of the
oxygen consumption rate (OCR) of third larvae (xL3s) (n = 600 per well) following exposure to individual test compounds (a-15 and a-17) and
reference controls (tolfenpyrad, tebufenpyrad and monepantel), tested at concentrations of 50 μM and 100 μM, respectively. The OCR data were
measured 35 times (2 min-mix 4 min-measure) for 30 min before and 180 min after exposure to each compound using a Seahorse XFe96 flux
analyser. Three separate experiments were conducted using 4 replicates in each experiment. Panels c and d show the total oxygen consumption
of xL3s (n = 600 per well; calculated from the area under the curve, AUC) following exposure to individual test compounds (a-15 and a-17) and
the reference control compounds (tolfenpyrad, tebufenpyrad and monepantel), tested at concentrations of 50 μM and 100 μM, respectively.
Variation was expressed as the standard error of the mean (SEM). Significance between values (mean ± SEM) was determined using a nonparametric
(Kruskal-Wallis) one-way ANOVA and Dunnett’s multiple comparison test. Asterisks indicate values that are significantly different from one another
(**P < 0.01; ****P < 0.0001)
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